Pharma/Medical Device/Diagnostics Licensing and Collaborations - Evaluating the Deal Structure

Provisional Table of Contents

EXECUTIVE SUMMARY

Chapter 1 Pharmaceutical business model and strategies

1.1 The Blockbuster Model – If it isn' t broken don' t fix it?

Chapter 2 The emergence of personalized medicine

2.1 The right drug for the right disease

2.2 The right drug for the right patient

2.3 Single Nucleotide Polymorphisms and Haplotypes

2.4 Herceptin and Breast Cancer

2.5 Beyond cancer – expanding the potential for personalized medicine

2.6 Prevention and prediction of disease predisposition

2.7 Business implications of pursuing personalized medicine

2.8 Pharmacogenomics and impact on drug development costs

2.9 Personalised medicine and the drug pipeline 31

2.10 Genomics and the probability of reducing attrition rates

2.11 The rise of the biotechnology industry 35

Chapter 3 Bridging the pharma-device-diagnostics divide–tapping the potential

3.1 The Medical Device Industry

3.1.1. Medical devices and therapeutics

3.1.2 Combination drug-device products

3.1.3 Angiotech and combination products

3.1.4 Medtronic and combination product development.

3.1.5 Targeting the eye

3.2 The Medical Diagnostics Industry

3.2.1 Pharmacogenomics to push pharma-diagnostic collaborations.

Chapter 4 Evaluation methodologies of suitable licensing candidates

4.1 Market size analysis

4.2 Market size estimation for targeted therapies

4.3 Evaluation methodologies and models

4.4 Discounted cash flow

4.5 Decision analysis

4.6 Decision analysis output

4.7 Sensitivity Analysis

4.8 Sensitivity analysis on values

4.9 Sensitivity analysis on probabilities

4.10 Value of Information

4.11 Value of perfect information

4.12 Value of imperfect information

4.13 Real Options

Chapter 5 Conclusion